Compare CRH & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRH | BDX |
|---|---|---|
| Founded | 1936 | 1897 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.8B | 55.1B |
| IPO Year | N/A | 1962 |
| Metric | CRH | BDX |
|---|---|---|
| Price | $126.25 | $201.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $129.54 | ★ $212.13 |
| AVG Volume (30 Days) | ★ 6.1M | 2.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | 1.17% | ★ 2.09% |
| EPS Growth | ★ 0.53 | N/A |
| EPS | 5.01 | ★ 5.82 |
| Revenue | ★ $36,901,000,000.00 | $21,840,000,000.00 |
| Revenue This Year | $6.75 | $4.00 |
| Revenue Next Year | $5.99 | $3.40 |
| P/E Ratio | ★ $25.37 | $34.52 |
| Revenue Growth | 4.28 | ★ 8.24 |
| 52 Week Low | $76.75 | $162.29 |
| 52 Week High | $127.44 | $251.99 |
| Indicator | CRH | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 66.35 | 65.48 |
| Support Level | $122.27 | $188.52 |
| Resistance Level | $127.10 | $196.12 |
| Average True Range (ATR) | 2.61 | 3.53 |
| MACD | 1.12 | 0.70 |
| Stochastic Oscillator | 95.36 | 88.65 |
CRH is a global manufacturer of a range of building products used in construction projects, operating via a vertically integrated business model. The past decade has seen CRH transform into a leading building materials business, with increasing exposure to upstream building activities such as aggregates and cement. CRH's geographic footprint is mostly across developed markets. North America is CRH's largest market and accounts for 75% of EBITDA. The company is the largest producer of aggregates and asphalt in the US.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.